HOLMDEL, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that the cyber-defense unit of one of the world’s most renowned defense ministries has placed over $600K in new orders for BIO-key’s biometric user authentication solution. The orders ...

The Bridgewater GTO Commission is a bespoke, open-top grand tourer blending Series I–III lineage, D-Type cues, and modern performance KISSIMMEE, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- ECD Automotive Design has unveiled its most ambitious creation yet: a Jaguar E-Type GTO, a bespoke, open-top grand tourer built from the ground up for a private client under what is now known as The Bridgewater Commission. View images and video of The Bridgewater Commission This one-of-one vehicle, dubbed the Jaguar E-Type G ...

Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data.The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivi ...

I wrote about GigaCloud Technology Inc. (NASDAQ: GCT ) last year as I liked its business model and long-term growth story. However, the industry that it is aiming to disrupt, cross-border trade and logistics, is facing economic disruptions due to theNine to 5 by day. Hobbyist stock trader by night. I got an MBA and a CFA ... so that should count for something. I only care about my own greedy interests and I love feeding trolls. Not your financial advisor. Information for entertainment purposes only. Diamond ...

Core Points - Aptose Biosciences Inc. has secured a short-term cash advance from Dr. William G. Rice to support near-term obligations and advance its clinical-stage oral kinase inhibitor, tuspetinib [1][2] - The cash advance is non-interest bearing, unsecured, and can be repaid at any time without penalty [2] - The advance is classified as a related-party transaction under Canadian securities laws, with exemptions from formal valuation and minority shareholder approval [3] - Without additional funding, Aptose may face insufficient financial resources to continue operations, potentially leading to insolvency proceedings [4] - Ms. Carol Ashe has resigned as a director of the Company, and the Company expresses gratitude for her contributions [5] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6] - The lead product, tuspetinib, has shown efficacy as a monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy for newly diagnosed AML [6]

Core Insights - ZenaTech, Inc. has launched the ZenaDrone's IQ Nano, an autonomous indoor drone aimed at US Department of Defense applications, focusing on inventory management, facility security, and search and rescue [1][2] - The company plans to pursue Green UAS certification, followed by Blue UAS certification, to be recognized as a secure drone supplier for military customers [1][6] Company Overview - ZenaTech specializes in AI drone technology, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, with a focus on mission-critical applications [7] - The company has been expanding its drone design and manufacturing capabilities since 2017, serving sectors such as law enforcement, government, agriculture, defense, logistics, and land surveying [7][9] Product Features - The IQ Nano drone is designed for operations in GPS-denied and high-risk environments, automating tasks like inventory management and enhancing safety through precise barcode scanning [2][3] - Equipped with HD and thermal imaging, the drone supports secure indoor surveillance and has capabilities for autonomous flight and night vision, aiding in search and rescue operations [3][4] - The drone can operate as part of a fleet, allowing for simultaneous coverage of large or complex facilities, improving efficiency in inventory audits and surveillance [5] Certification Process - The Green UAS certification is a commercial certification for secure drones, while the Blue UAS certification is a military-grade approval that includes stringent security and performance evaluations [6]

Core Insights - Sarepta Therapeutics experienced a significant stock decline of 42% following the announcement of a second patient death linked to its gene therapy, Elevidys, leading to the suspension of its use in non-ambulatory patients for safety reviews [2][3] - Roche's reassessment of the safety profile prompted the immediate cessation of commercial distribution and a pause in ongoing clinical trials until risk mitigation measures are established [3] - Elevidys, which accounted for 43% of Sarepta's total revenues last year, was projected to achieve peak sales exceeding $3 billion, but these expectations are now under threat due to the restricted patient population [5] Financial Overview - Sarepta's financial situation was already precarious, with an operating cash flow margin of negative 25% and a net income margin of negative 11%, despite average revenue growth exceeding 40% over the past three years [6] - The company carries $1.3 billion in debt against a market capitalization of $2.06 billion, resulting in a debt-to-equity ratio of 63% [6] - The stock has seen extreme volatility, dropping from a 52-week high of approximately $172 to around $20, highlighting the risks associated with reliance on a limited number of drug revenues [7] Investment Considerations - The recent safety concerns surrounding Elevidys, combined with the company's heavy reliance on a single revenue source and significant cash burn, create a highly speculative investment environment [8] - While Sarepta's low valuations may attract contrarian investors, the investment carries substantial risks, making it suitable only for those with a high risk tolerance [8] - Investors may consider diversified investment strategies, such as the Trefis High Quality Portfolio, which spreads risk across multiple companies and sectors, rather than concentrating on individual stocks [9][10]

Core Viewpoint - Sanofi has successfully priced a €1.5 billion bond issue, which will be utilized for general corporate purposes [1]. Group 1: Bond Issue Details - The bond issue consists of two tranches, each amounting to €750 million [7]. - The first tranche is due in June 2029 with an annual interest rate of 2.625% [7]. - The second tranche is due in June 2032 with an annual interest rate of 3.000% [7]. Group 2: Transaction Management - The transaction was led by Citigroup and RBC Capital Markets as Global Coordinators [2]. - Credit Agricole CIB, HSBC, and Societe Generale acted as Joint Lead Managers for the bond issue [2]. Group 3: Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines [3]. - The company aims to address urgent healthcare, environmental, and societal challenges [3]. - Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY [3].

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSX.V: LFST; OTCQB: LFSWF; FRANKFURT: M5B0), a health-tech wellness company advancing the science of human performance, announces the launch of the Mind-First Movement through its performance-focused brand Mikra. This brand evolution positions mental performance as the essential foundation of high performance, both in sport and in life. The Mind-First Movement reflects a growing recognition in achieving high-perfo ...

Digital Turbine (NASDAQ: APPS ) reported mixed results in the fourth quarter of FY25, but this is enough to drive the stock higher at the moment. While Digital Turbine's business continues to struggle, it appears to haveRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth ...